Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

Phase 1

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 3(2)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03742557Phase 3Unknown

Evaluation of Schemes of Administration of Intravenous Ketamine in Depression

Role: lead

NCT02188914Completed

Brain Imaging Studies of the Effect of Inhalant Use Disorder

Role: collaborator

NCT02610712Phase 4Unknown

Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

Role: lead

NCT01061866Phase 1Completed

Thalidomide Low Threshold in Epilepsy

Role: lead

NCT00224978Phase 3Completed

Chloroquine for Treatment of Glioblastoma Multiforme

Role: lead

All 5 trials loaded